GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » Price-to-Owner-Earnings

Arcus Biosciences (Arcus Biosciences) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences Price-to-Owner-Earnings?

As of today (2024-04-28), Arcus Biosciences's share price is $15.55. Arcus Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Arcus Biosciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 8 years, the highest Price-to-Owner-Earnings of Arcus Biosciences was 7.14. The lowest was 3.38. And the median was 4.75.


RCUS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), Arcus Biosciences's share price is $15.55. Arcus Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.15. Therefore, Arcus Biosciences's PE Ratio for today is At Loss.

As of today (2024-04-28), Arcus Biosciences's share price is $15.55. Arcus Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-4.15. Therefore, Arcus Biosciences's PE Ratio without NRI for today is At Loss.

During the past 8 years, Arcus Biosciences's highest PE Ratio without NRI was 94.12. The lowest was 0.00. And the median was 38.49.


Arcus Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Arcus Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcus Biosciences Price-to-Owner-Earnings Chart

Arcus Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - 4.25 -

Arcus Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 - - - -

Competitive Comparison of Arcus Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Arcus Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcus Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Price-to-Owner-Earnings falls into.



Arcus Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Arcus Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=15.55/-5.09
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcus Biosciences  (NYSE:RCUS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Arcus Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcus Biosciences (Arcus Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Executives
Goeltz Ii Robert C. officer: Chief Financial Officer 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen director, 10 percent owner, officer: President 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett officer: See Remarks C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy officer: Chief Accounting Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen director, 10 percent owner, officer: Chief Executive Officer C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang officer: General Counsel 3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten officer: Chief Medical Officer 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins director 3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert director 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman officer: Chief Medical Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko director, 10 percent owner 509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman director 618 MIRADA AVE, STANFORD CA 94305

Arcus Biosciences (Arcus Biosciences) Headlines